Article citationsMore>>

C. B. Hicks, E. DeJesus, L. M. Sloan, et al., “Comparison of Once-Daily Fosamprenavir Boosted with either 100 or 200 mg of Ritonavir, in Combination with Abacavir/ Lamivudine: 96-Week Results from COL100758,” AIDS Research and Human Retroviruses, Vol. 25, No. 4, 2009, pp. 395-403. doi:10.1089/aid.2008.0231

has been cited by the following article:

• TITLE: Impact of Switch to Fosamprenavir and Addition of Lovaza® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

  AUTHORS: Franco Felizarta, Anthony Scarsella, Homayoon Khanlou, Winston Young, Lisa Ross, Henry Zhao, Keith Pappa, Belinda Ha

  KEYWORDS: Fish Oil; Fosamprenavir; HIV; Hypertriglyceridemia; Lovaza; Switch; Triglycerides

  JOURNAL NAME: World Journal of AIDS, Vol.2 No.1, March 22, 2012

  ABSTRACT: Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug interactions. For this study, we examined a dual strategy to manage hypertriglyceridemia in HIV-infected patient taking PIs: 1) switching patients to fosamprenavir (FPV), a PI with fewer drug interactions, and 2) adding prescription fish oil (LOVAZA?), which has been shown to reduce triglycerides. Methods: This multicenter, 24-week study enrolled 36 patients virologically suppressed (HIV-1 RNA